Skip to main content
NewslettersWatchlist

Pacira Pharm Inc(PCRX-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low26.27
Day High27.12
Open:26.28
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
Globe Newswire
Pacira BioSciences Reports Preliminary Net Product Sales of $50.2 Million for July 2022
Globe Newswire
NFL Alumni Association and Pacira BioSciences Team Up to Educate Athletes and Communities About Non-Opioid Options to Manage Pain
Globe Newswire
Pacira BioSciences Reports Second Quarter 2022 Financial Results
Globe Newswire
Pacira BioSciences to Participate in Fireside Chat at the 2022 Wedbush PacGrow Healthcare Virtual Conference
Globe Newswire
Pacira to Report Second Quarter 2022 Financial Results on Wednesday August 3, 2022
TipRanks
Pacira Pharmaceuticals (PCRX) Received its Third Buy in a Row
Globe Newswire
Pacira BioSciences Reports Preliminary Second Quarter 2022 Revenue of $169.4 Million
PR Newswire
National Safety Council and Pacira BioSciences Partner to Launch an Employee-Based Program Focused on Opioid Use and Misuse
Globe Newswire
Pacira BioSciences Reports Preliminary Net Product Sales for EXPAREL and iovera° of $46.0 Million for May 2022
Globe Newswire
Pacira BioSciences to Participate in Fireside Chat at the Jefferies Healthcare Conference
Globe Newswire
Pacira BioSciences Reports First Quarter 2022 Financial Results
Motley Fool
3 Small-Cap Medical Stocks With Big Momentum
Globe Newswire
Pacira BioSciences to Participate in Fireside Chat at the 21st Annual Needham Virtual Healthcare Conference
Globe Newswire
Pacira BioSciences to Participate in Fireside Chat at the Barclays Global Healthcare Conference
Globe Newswire
Pacira BioSciences Reports Full-Year and Fourth Quarter 2021 Financial Results
Globe Newswire
Pacira to Report 2021 Financial Results on Thursday February 24, 2022
Globe Newswire
Pacira BioSciences Reports Preliminary Net Product Sales for EXPAREL and iovera° of $37.3 Million for January 2022
Globe Newswire
Pacira BioSciences Announces Closing of $375 Million Five-Year Term Loan B
Globe Newswire
Pacira BioSciences Reports Preliminary Net Product Sales for EXPAREL® and iovera° of $48.0 Million for November 2021
Globe Newswire
Pacira BioSciences to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference
Globe Newswire
Pacira BioSciences Completes Acquisition of Flexion Therapeutics and Strengthens Leadership Position in Non-Opioid Pain Management
Globe Newswire
Pacira BioSciences Reports Preliminary Net Product Sales of $44.3 Million for October 2021
Globe Newswire
Pacira Files Lawsuit Against eVenus for Patent Infringement
Globe Newswire
Pacira BioSciences Reports Third Quarter 2021 Financial Results
Globe Newswire
Pacira Receives Notice of Allowance for New Patent Covering EXPAREL Composition
Globe Newswire
Pacira to Report Third Quarter 2021 Financial Results on Wednesday November 3, 2021
Globe NewsWire
Pacira Announces Commercial Production Underway with Enhanced EXPAREL Manufacturing Process at Swindon Facility
Business Wire
ImmuneID Appoints Veteran Biotech Executive James S. Scibetta as CEO
Globe NewsWire
Pacira Announces Publication of Phase 3 Study of EXPAREL Infiltration in Pediatric Patients Undergoing Spinal or Cardiac Surgeries
Globe NewsWire
Pacira BioSciences Reports Preliminary Net Product Sales of $42.3 Million for August 2021
Globe NewsWire
Pacira BioSciences to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
Globe NewsWire
Pacira BioSciences Reports Preliminary Net Product Sales of $42.1 Million for July 2021

Profile

Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on the development, commercialization and manufacture of proprietary pharmaceutical products primarily for use in hospitals and ambulatory surgery centers. These products are developed using the company's proprietary DepoFoam drug delivery technology. Pacira changed its name to Pacira BioSciences following the acquisition of MyoScience. Exparel, the company's flagship product, is a liposome injection of bupivacaine, which is indicated for single-dose administration into the surgical site to produce postsurgical analgesia. The company signed a licensing agreement with Aratana for the development and commercialization of Exparel for animal health indications.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.